Pharmagreen Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pharmagreen Biotech generated cash of -$73,838, which is more than the previous year. Cash used in financing activities reached the amount of $83,373 last year. Net change in cash is therefore -$6,762.
Cash Flow
| 2017 | -21.08K | -3.91K | 38.53K |
|---|---|---|---|
| 2018 | -785.53K | -251.31K | 1.12M |
| 2019 | -317.83K | -196.12K | 432.82K |
| 2020 | -607.63K | 0 | 562.62K |
| 2021 | -206.08K | 0 | 257.49K |
| 2022 | -426.56K | 0 | 313.70K |
| 2023 | -73.83K | 0 | 83.37K |
PHBI Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.01K | 25.3K | 12.19K | 62.68K | 151.86K | 16.44K | 10 |
Operating activities | |||||||
Net income | -568.77K | -875.50K | -4.53M | -2.43M | -768.81K | -1.07M | -18.98K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 76.37K | 461.03K | 627.67K | 10.78K | 172.5K | 0 | 0 |
| Deferred income tax benefit | 76.37K | 461.03K | 627.67K | 10.78K | 172.5K | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -225 | -93 | 5 | 10.34K | 21.12K | 0 | -1.73K |
Inventories | -8.77K | 0 | -5 | -10.34K | -21.12K | 0 | 0 |
Accounts payable | 0 | 65.43K | 147.65K | -16.22K | 231.08K | 18.37K | 0 |
Cash generated by operating activities | -73.83K | -426.56K | -206.08K | -607.63K | -317.83K | -785.53K | -21.08K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | -196.12K | -251.31K | -3.91K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | -196.12K | -251.31K | -3.91K |
Financing activities | |||||||
Common Stock Issued | 0 | 187K | 267.72K | 40K | 390 | 0 | 12.42K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 126.70K | -43.88K | -168.54K | 263.11K | -104.25K | 14.30K |
Cash used in financing activities | 83.37K | 313.70K | 257.49K | 562.62K | 432.82K | 1.12M | 38.53K |
Net Change In Cash | -6.76K | -17.28K | 13.10K | -50.48K | -89.18K | 135.42K | 11 |
Cash at end of period | 1.25K | 8.01K | 25.3K | 12.19K | 62.68K | 151.86K | 21 |
| Data source | Data source | Data source | Data source |